<SEC-DOCUMENT>0001144204-15-057409.txt : 20150930
<SEC-HEADER>0001144204-15-057409.hdr.sgml : 20150930
<ACCEPTANCE-DATETIME>20150930161528
ACCESSION NUMBER:		0001144204-15-057409
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150925
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150930
DATE AS OF CHANGE:		20150930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		151133918

	BUSINESS ADDRESS:	
		STREET 1:		20 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		20 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v421319_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C.&nbsp;20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): September 25, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <TD STYLE="width: 32%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</td>
    <TD STYLE="width: 34%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</td>
    <TD STYLE="width: 32%">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center"><b>Delaware</b></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: center"><b>0-26770</b></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: center"><b>22-2816046</b></td></tr>
<tr>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or Other Jurisdiction</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of Incorporation)</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: center"><font style="font-size: 10pt"><b>(Commission File Number)</b></font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Firstfield Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gaithersburg, Maryland 20878</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of Principal Executive Offices,
including Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(240) 268-2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>(Former name or former
address, if changed since last report.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 33%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Item 1.01. Entry into a Material Definitive
Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 25,
2015, Novavax, Inc. (the &ldquo;Company&rdquo;), entered into an agreement (&ldquo;Grant Agreement&rdquo;) with the Bill and Melinda
Gates Foundation (&ldquo;BMGF&rdquo;), under which the Company was awarded a grant totaling up to $89.1 million (the &ldquo;Grant&rdquo;)
to support the development of its respiratory syncytial virus F-protein recombinant nanoparticle vaccine candidate (&ldquo;RSV
F Vaccine&rdquo;) for the protection of infants via maternal immunization (the &ldquo;Project&rdquo;). The Grant will support key
development milestones, including a global Phase 3 clinical trial in pregnant women in their third trimester, product licensing
efforts and WHO prequalification (&ldquo;WHOPQ&rdquo;) of the RSV F Vaccine, with the expectation that the vaccine would be made
available by Novavax in certain middle and low income countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company
concurrently entered into a Global Access Commitments Agreement (&ldquo;GACA&rdquo;) with BMGF as a part of the Grant
Agreement. Under the terms of the GACA, among other things, the Company agreed to make the RSV F Vaccine available and
accessible at affordable pricing to people in certain low and middle income countries. In addition, under the GACA, the
Company made certain volume production and pricing commitments. Unless earlier terminated by BMGF, the GACA will continue in
effect until the latter of 15 years from its effective date, or 10 years after the first sale of a product under defined
circumstances, unless earlier terminated by BMGF. The term of the GACA may be extended in certain circumstances, by a period
of up to five additional years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing
descriptions of the Grant and GACA do not purport to be complete and are qualified in their entirety by references to the Company&rsquo;s
Grant and GACA, which will be filed with the Securities and Exchange Commission as exhibits to the Company&rsquo;s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Item 8.01.
Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 29,
2015, the Company issued a press release announcing this transaction. A copy of this press release is attached as exhibit 99.1
to this Current Report on Form 8-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Exhibits</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Exhibit No.</b></font></td>
    <td style="vertical-align: top; width: 5%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 12%; border-bottom: Black 1pt solid"><font style="font-size: 10pt"><b>Description</b></font></td>
    <td style="vertical-align: bottom; width: 75%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">99.1</P></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">Press
Release, dated September 29, 2015, regarding award of BMGF Grant.</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD COLSPAN="4"><font style="font-size: 10pt">Novavax, Inc.</font><br>
<font style="font-size: 10pt">(Registrant)</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%"><font style="font-size: 10pt">Date: September 30, 2015</font></td>
    <TD STYLE="width: 5%"><font style="font-size: 10pt">By:</font></td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="width: 29%; text-decoration: none; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John A. Herrmann III</FONT></TD>
    <TD STYLE="width: 15%; text-decoration: none">&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">Name:</font></td>
    <TD>&nbsp;</td>
    <TD COLSPAN="2"><font style="font-size: 10pt">John A. Herrmann III</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">Title:</font></td>
    <TD>&nbsp;</td>
    <TD COLSPAN="2"><font style="font-size: 10pt">Senior Vice President, General Counsel and Corporate Secretary</font></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Exhibit No.</b></font></td>
    <td style="vertical-align: top; width: 5%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 12%; border-bottom: Black 1pt solid"><font style="font-size: 10pt"><b>Description</b></font></td>
    <td style="vertical-align: bottom; width: 75%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">99.1</P></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">Press
Release, dated September 29, 2015, regarding award of BMGF Grant.</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><BR>
<BR>
</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v421319_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>Novavax
Announces Grant of up to $89 Million to Support Development of RSV F Vaccine to Protect Infants via Maternal Immunization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Bill &amp; Melinda Gates Foundation to
support development of the RSV F Vaccine Program</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Gaithersburg,
Md., September 29, 2015 &ndash; Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development
and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced</FONT> it has been awarded a grant of
up to $89 million from the Bill &amp; Melinda Gates Foundation to support development of the RSV F Vaccine Phase 3 clinical trial
in pregnant women, planned to initiate during the first quarter of 2016. <FONT STYLE="background-color: white">This grant will
also support regulatory licensing efforts, providing a path to WHO prequalification. </FONT>Upon licensure, Novavax has agreed
to make the RSV F Vaccine <FONT STYLE="background-color: white">affordable and accessible </FONT>to people in the developing world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Respiratory
syncytial virus (RSV) is the leading cause of pneumonia in infants, and currently there are no affordable approaches to protecting
children in the developing world from this viral disease,&rdquo; said Dr. Keith Klugman, Director of the Bill &amp; Melinda Gates
Foundation&rsquo;s Pneumonia Program. &ldquo;Maternal immunization may provide protective antibodies to infants during the first
few months of life, and we hope this vaccine will protect infants from this disease to help them live healthy, productive lives.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Along
with today&rsquo;s announcement of top-line data from the Phase 2 clinical trial of our RSV F Vaccine with the goal to protect
infants via maternal immunization, we are very gratified to receive the support of the Bill &amp; Melinda Gates Foundation to improve
the health of infants throughout the world,&rdquo; said Stanley C. Erck, President and CEO. &ldquo;Our groundbreaking Phase 2 results
in both maternal and older adult target populations, underscore the promise of our RSV F Vaccine programs. We look forward to carrying
our recent momentum into the fourth quarter as we prepare to initiate two pivotal Phase 3 trials of our RSV F Vaccine.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">A
fact sheet on maternal immunization is available at the Novavax website, </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Blue; background-color: white"><U>http://novavax.com/download/files/pipeline/151_Novavax_FactSheet_FIN_D_9x10.pdf
</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
RSV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Respiratory syncytial virus (RSV) is the
most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in
infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively<SUP>1</SUP>.
In the US, RSV is the leading cause of hospitalization of infants<SUP>2</SUP>. Despite the induction of post-infection immunity,
repeat infection and lifelong susceptibility to RSV is common<SUP>3,4</SUP>. Currently, there is no approved RSV vaccine available.
Palivizumab is a monoclonal antibody, licensed and sold by MedImmune as Synagis<SUP>&reg;</SUP>, that targets the RSV F protein
and is used for prophylaxis against RSV disease in high risk infants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Novavax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N<FONT STYLE="background-color: white">ovavax,
Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious
diseases. Our recombinant nanoparticles and Matrix-M&trade; adjuvant technology are the foundation for groundbreaking innovation
that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company&rsquo;s
website, novavax.com</FONT><FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>References:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Nair, H. <I>et al.</I> Global burden of acute lower respiratory infections due to respiratory syncytial
virus in young children: a systematic review and meta-analysis. <I>Lancet</I>, 2010; 375: 1545-1555.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Hall, C.B. <I>et al.</I> Respiratory Syncytial Virus-Associated hospitalizations Among Children
Less Than 24 Months of Age. <I>Pediatrics</I>, 2013; 132(2): E341-348.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Glezen, W.P. <I>et al.</I> Risk of primary infection and reinfection with respiratory syncytial
virus. <I>Am J Dis Child</I>, 1986; 140:543-546.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Glenn GM, <I>et al.</I> Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea
pigs. <I>Vaccine,</I> 2015; In press. http://dx.doi.org/10.1016/j.vaccine.2015.08.039.<FONT STYLE="background-color: white"> </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Contact:</TD><TD>Novavax, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Barclay A. Phillips</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">SVP, Chief Financial Officer and
Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Andrea N. Flynn, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Senior Manager, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; color: blue"><U>ir@novavax.com
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">240-268-2000</P>

<P STYLE="font: 10pt Courier; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Courier; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Russo Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">David Schull</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Todd Davenport, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="color: Blue"><U>david.schull@russopartnersllc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="color: Blue"><U>todd.davenport@russopartnersllc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">212-845-4271</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I 0@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#EO^$AUO\
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MCL58'^5:)0Q-/322,VY8>IKJF>F_%/QQ-#<#0=)N7B>,AKN>)RK ]HP1^9_
M>M97P\TK7O%&H_:[O5M2&E6S#S#]JD'G-_<'/3U_+O7+^%O#5[XPUW[.KN(]
MWF7=RW.Q2>3[L>U?1VFZ;:Z1IT%A91"*WA7:BC^9]2?6HK2C0A[..Y5*,JT_
M:2V+8&!@4445YYWGR7;_ /'U!_UT7^8KZ&^(?A4>)O#K>0@.H6F9;<]VX^9/
MQ'Z@5\\VY'VJ#G_EHO\ ,5]:5Z6-FX2C)'GX2*E&46?+_AC7[CPSX@M]2B#$
M(=DT?3?&?O+]?ZBF^*KJ&^\5ZK=V[B2":X:2-QW4\BNK^*OA7^QM:_M>UCQ9
M7S$N .(YNX^C=?KFO/21@UU4W&=JBZHYJBE"]-GO\]E)J/P76VB&9&TM&4#N
M54-C]*\ /S)QW%?3W@_GP7HW_7G'_P"@BO*?'/PSOM/O9M1T.W:YL)&+M!&,
MO 3R0!W7Z<BN3#5HQG*$NK.K$TI2C&2Z(]9\+:K!K/AG3[V!PP:%5<#^%P,,
M#]"*V*^7=&\2ZSX9N'_LZ\DMBQ_>0NN58^ZGO^M;=U\5?%=S 8OM\$ (P7AA
M"M^9SBHG@IN7NO0J.,CR^\M3;^,VJ0W6N6&G1.&>TB9I<?PL^,#ZX&?QK(^%
M-G)=>/;655)2VBDE<^GR[1^K5SFFZ1J_B.]*V-K<7D\C9>3DC)ZEG/ _$U[U
MX$\&1^$=+=9'674+C#7$J]!CHJ^P_6MJLHT:/LT]3*G&5:K[2VAT&JZ=#J^D
MW6G7 S%<Q-&WMD=?P/-?+=W:W.E:E-:RY2ZM92A([,IZ_P!:^L*\1^,6@_8]
M:M]:B3$5ZOERD#I(HX/XK_*L,%4M)P?4VQE.\5)=#=\;>,4N_A?8S0OBXU=1
M&P'\('^L_48_&N.^%N@_VQXNCN94S;:>//;/0OT0?GS^%<;)=RR6T,$DK&&#
M<8T)X7<<MCZD5] _#'0?[$\(0R2IMNKX_:)<CD CY1^ Q^9K>HEAZ+BMW_7Y
M&5-NO53?0WO$FN0^'= N]3FP?*3]VI_C<\*OXFOF"YN)KRYFN;B0O/,YDD<]
MV)R37HGQ>\2B_P!9CT2WDS;V/S38/#2D=/\ @(_4FF_#'P19>(HKS4=6@,MF
MA\F%-Q7<_5FR/3@?B:6'4:%+VDNH5VZU3V<>A<TKXNVFCZ5:Z=:^'W$-O&(U
M_P!)'..I^[U)Y_&N2\:>*+;Q;J4%_%IS6<Z1^7(3*'$@!^7L.1S7L?\ PJ_P
MA_T"C_W_ )/\:9/\+/"<D$B1:>T4C*0L@F<E3C@X)J(5\/&7,D[ERHUY1Y6U
M8\N^&/B/^P?%*6\S[;._Q#)D\*_\#?F<?C7NFN:5%KFB7FF3XV7$13/]T]C^
M!P:^7K^SGTS4;BQN04N+>0QO]0>H_G7T1\/_ !(/$OA:":1PUY;_ +BY'?<!
MPWXC!_.C&0LU5C_78,).Z=.1\\.EUI>HLC9BN[2;!]5=3_B*]=^(?BZ.[^'F
MG?9FP^L*I8#^%%P7'_?6!^=<]\7M!_L[Q%%JT28@OU^?'02J,'\Q@_@:\_EN
MY98((996:*W5EB4GA 3DX_$YKI48UE"IV_K\SG<I4>:'<[GX3Z#_ &KXJ^WR
MIFWTY?,YZ&0\*/PY/X"O9_$6M0^'M!N]3GP1"F47^^YX5?Q.*Q_ASH']@^$+
M9)4VW5U_I$V>H+#@?@,?K7G_ ,8/$@O-4AT&"3,-I^\GP>LA' _ '\S7'+_:
M*]NB.J/[BC?J><75S-?74UU<R%YYW,DC^K$Y->GZ;\7[32M,MK"V\/.L-O&L
M:#[2.@'7[OXU2^&/@BR\10WFHZO TMFA$,*;BNY^K'(].!^)KT'_ (5?X0_Z
M!1_[_P G^-;UZU&_)-7L8T:5:W/%VN>,>,?$=OXIUE=2AL&LY3$$E!DW[R.A
MZ#MQ^ KHOA)XB_LSQ ^DSOBVU#[F3PLHZ?F./P%=]??"OPQ+87$=I8F"Y:-A
M%+YSG8V.#@GUKP-A<:??%6W0W5M+@]BCJ?\ $5<)4ZU-TXDSC4HS4Y'OGQ$\
M;KX9T[['9.#JMRO[L=?)7NY_H/7Z5X;I^DZGKDEVUG!)=201-<3MG)QW.>Y/
MIU-)<7.H>(M:,LA>ZU"\D  '5F/  '8?RKZ'\%^%8?"FA):C:]W)B2YE'\3^
M@]AT'_UZS;CA:=EK)EI/$SUT2/!?"OB:Z\+:S'?V^7A;Y9X<\2IZ?4=0:^DM
M,U*TUC38+^RE$MO,NY&'\CZ$=*\4^)_@O^P]0.L6$6-.NG_>*HXAD/\ [*>W
MOQZ53^'?C9O#&I?8[R0G2KEOGS_RQ?\ OCV]?S[45J:KP]I#<*-1T9^SGL?0
M5%(K*Z!T8,K#((.01ZT5YAZ)%]DMO^?>+_O@5-110 UXTD7:Z*P]&&14?V6V
M_P"?>+_O@5-11<!%4*H50 !T %+110!4N]*TZ_.;RPM;@^LL*L?U%5(_"_A^
M)]R:)IZMZBV3_"M:BFI-;,7*NPR.*.&,1Q1K&@Z*@P!^%/HHI#"FO&D@Q(BN
M/1AFG44 0_9+;_GWA_[X%3  # Z444 1&VMV))@B)/))04]$2-=J*JKZ*,"G
M44 %%%% $;6\#L6:&-F/4E 2:5(HXL^7&B9Z[5 S3Z* &O%'* )$5P.@89J/
M[);?\^\/_? J:BBX!436T#,6:"(D\DE!S4M% #41(UVHJJOHHP*=110 5$;:
M!F+-!$2>22@YJ6B@");>!&#+#&K#H0@!%2T44 5M0L+;5-/GL;R(2V\Z%'0]
MP?ZU\U^*_#5SX6UR73Y\O$?GMYB.)(^Q^HZ&OIVO)_C=_P >VB_]=)?Y+79@
MZC53EZ,Y,7!.'-U1#\*_'&TQ^'-3EX/%E*Q_\AG^GY>E%>66/_(2M/\ KO'_
3 .A"BM,3AUSW6ER,/6?)9]#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
